Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1482

1.

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial.

Plitt A, Ruff CT, Goudev A, Morais J, Ostojic MC, Grosso MA, Lanz HJ, Park JG, Antman EM, Braunwald E, Giugliano RP.

Int J Cardiol. 2020 Jan 30. pii: S0167-5273(19)35229-5. doi: 10.1016/j.ijcard.2020.01.009. [Epub ahead of print]

PMID:
32008850
2.

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

Zelniker TA, Braunwald E.

J Am Coll Cardiol. 2020 Feb 4;75(4):435-447. doi: 10.1016/j.jacc.2019.11.036. Review.

PMID:
32000956
3.

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

Zelniker TA, Braunwald E.

J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. doi: 10.1016/j.jacc.2019.11.031. Review.

PMID:
32000955
4.

Atrial Failure as a Clinical Entity: JACC Review Topic of the Week.

Bisbal F, Baranchuk A, Braunwald E, Bayés de Luna A, Bayés-Genís A.

J Am Coll Cardiol. 2020 Jan 21;75(2):222-232. doi: 10.1016/j.jacc.2019.11.013. Review.

5.

Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial).

Alkhalfan F, Nafee T, Yee MK, Chi G, Kalayci A, Plotnikov A, Braunwald E, Gibson CM.

Am J Cardiol. 2020 Mar 1;125(5):661-669. doi: 10.1016/j.amjcard.2019.12.007. Epub 2019 Dec 9.

PMID:
31898965
6.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.

Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue ML.

J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022. doi: 10.1016/j.jacc.2019.09.065. Epub 2019 Dec 9.

PMID:
31865968
7.

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.

DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ; PIONEER-HF Investigators.

JAMA Cardiol. 2019 Dec 11. doi: 10.1001/jamacardio.2019.4665. [Epub ahead of print]

PMID:
31825471
8.

Baseline Characteristics of the VANISH Cohort.

Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY.

Circ Heart Fail. 2019 Dec;12(12):e006231. doi: 10.1161/CIRCHEARTFAILURE.119.006231. Epub 2019 Dec 9.

PMID:
31813281
9.

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.

Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP.

Eur Heart J. 2019 Dec 7. pii: ehz821. doi: 10.1093/eurheartj/ehz821. [Epub ahead of print]

PMID:
31811715
10.

Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.

Inciardi RM, Giugliano RP, Claggett B, Gupta DK, Chandra A, Ruff CT, Antman EM, Mercuri MF, Grosso MA, Braunwald E, Solomon SD; ENGAGE AF-TIMI 48 Investigators.

Eur J Heart Fail. 2019 Dec;21(12):1571-1579. doi: 10.1002/ejhf.1606. Epub 2019 Nov 27.

PMID:
31777160
11.

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.

Bhatt DL, Verma S, Braunwald E.

Cell Metab. 2019 Nov 5;30(5):847-849. doi: 10.1016/j.cmet.2019.10.008.

PMID:
31693879
12.

Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study.

Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E.

J Card Fail. 2019 Nov 2. pii: S1071-9164(19)30584-6. doi: 10.1016/j.cardfail.2019.10.011. [Epub ahead of print]

PMID:
31682908
13.

Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.

Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F, Kuder JF, Mercuri MF, Lanz HJ, Braunwald E, Giugliano RP.

Circulation. 2019 Nov 26;140(22):1792-1801. doi: 10.1161/CIRCULATIONAHA.119.041346. Epub 2019 Oct 10.

PMID:
31597460
14.

Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.

Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS.

Circulation. 2019 Nov 5;140(19):1569-1577. doi: 10.1161/CIRCULATIONAHA.119.042685. Epub 2019 Aug 31.

PMID:
31474116
15.

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.

Qamar A, Giugliano RP, Bohula EA, Park JG, Jarolim P, Murphy SA, Blazing MA, Califf RM, Cannon CP, Braunwald E, Morrow DA.

J Am Coll Cardiol. 2019 Aug 27;74(8):1057-1068. doi: 10.1016/j.jacc.2019.06.038.

PMID:
31439215
16.

Diabetes, heart failure, and renal dysfunction: The vicious circles.

Braunwald E.

Prog Cardiovasc Dis. 2019 Jul - Aug;62(4):298-302. doi: 10.1016/j.pcad.2019.07.003. Epub 2019 Aug 1. Review.

PMID:
31377223
17.

Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial.

Bergmark BA, Bhatt DL, McGuire DK, Cahn A, Mosenzon O, Steg PG, Im K, Kanevsky E, Gurmu Y, Raz I, Braunwald E, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators.

Circulation. 2019 Sep 17;140(12):1004-1014. doi: 10.1161/CIRCULATIONAHA.119.040144. Epub 2019 Jul 31.

PMID:
31362530
18.

Featuring: Eugene Braunwald.

Braunwald E.

Eur Cardiol. 2019 Jul 11;14(2):130-133. doi: 10.15420/ecr.2019.14.2.CM1. eCollection 2019 Jul. No abstract available.

19.

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.

Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, Antman EM, Braunwald E, Giugliano RP.

Hypertension. 2019 Sep;74(3):597-605. doi: 10.1161/HYPERTENSIONAHA.119.13138. Epub 2019 Jul 29.

PMID:
31352829
20.

Impact of ADCY9 Genotype on Response to Anacetrapib.

Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R; HPS3/TIMI55 - REVEAL Collaborative Group.

Circulation. 2019 Jul 23. doi: 10.1161/CIRCULATIONAHA.119.041546. [Epub ahead of print]

21.

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.

Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA.

JAMA Cardiol. 2019 Jul 17. doi: 10.1001/jamacardio.2019.2306. [Epub ahead of print]

PMID:
31314050
22.

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.

Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2019 Jul 16;74(2):179-189. doi: 10.1016/j.jacc.2019.04.061.

PMID:
31296289
23.

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.

Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206. doi: 10.1093/ehjcvp/pvz020.

24.

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.

Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E.

Eur Heart J. 2019 Oct 21;40(40):3345-3352. doi: 10.1093/eurheartj/ehz240.

25.

Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes.

Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MS, Morrow DA.

J Am Heart Assoc. 2019 May 7;8(9):e011444. doi: 10.1161/JAHA.118.011444.

26.

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM.

Clin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.

PMID:
30988169
27.

Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.

Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E.

Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331. No abstract available.

PMID:
30955360
28.

The Evidence Supporting Cardiovascular Guidelines: Is There Evidence of Progress in the Last Decade?

Bonow RO, Braunwald E.

JAMA. 2019 Mar 19;321(11):1053-1054. doi: 10.1001/jama.2019.2018. No abstract available.

PMID:
30874738
29.

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs.

Zelniker TA, Braunwald E.

Card Fail Rev. 2019 Feb;5(1):27-30. doi: 10.15420/cfr.2018.44.1. Review.

30.

Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.

Bergmark BA, Udell JA, Morrow DA, Jarolim P, Kuder JF, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS.

Eur J Heart Fail. 2019 Apr;21(4):462-470. doi: 10.1002/ejhf.1424. Epub 2019 Feb 18.

PMID:
30773798
31.

Medication Discontinuation in the IMPROVE-IT Trial.

Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, Giugliano RP, Tershakovec AM, Braunwald E, Califf RM, Blazing MA.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e005041. doi: 10.1161/CIRCOUTCOMES.118.005041.

32.

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.

Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Eur Heart J. 2019 May 14;40(19):1541-1550. doi: 10.1093/eurheartj/ehy861.

PMID:
30624719
33.

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.

Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Eur Heart J. 2019 May 14;40(19):1518-1527. doi: 10.1093/eurheartj/ehy807.

PMID:
30590425
34.

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA.

Circulation. 2019 Feb 5;139(6):760-771. doi: 10.1161/CIRCULATIONAHA.118.038312.

35.

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.

Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS.

J Am Heart Assoc. 2018 Nov 20;7(22):e009260. doi: 10.1161/JAHA.118.009260.

36.

High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.

Fudim M, Ambrosy AP, Sun JL, Anstrom KJ, Bart BA, Butler J, AbouEzzeddine O, Greene SJ, Mentz RJ, Redfield MM, Reddy YNV, Vaduganathan M, Braunwald E, Hernandez AF, Borlaug BA, Felker GM.

J Am Heart Assoc. 2018 Dec 18;7(24):e010364. doi: 10.1161/JAHA.118.010364.

37.

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Braunwald E, Hamershock RA, Murphy SA, Nieminen M, Lanz HJ, Mercuri MF, Peterson N, Antman EM, Giugliano RP.

Europace. 2019 Feb 1;21(2):306-312. doi: 10.1093/europace/euy253.

PMID:
30462220
38.

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators.

N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090.

PMID:
30415601
39.

Treatment of Hypertension: Addressing a Global Health Problem.

Qamar A, Braunwald E.

JAMA. 2018 Nov 6;320(17):1751-1752. doi: 10.1001/jama.2018.16579. No abstract available.

PMID:
30398610
40.

Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.

Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, LeWinter MM, Mann DL, Margulies KB, Smith AL, Tang WHW, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM; National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network.

JAMA. 2018 Nov 6;320(17):1764-1773. doi: 10.1001/jama.2018.14852.

41.

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.

Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):934-943. doi: 10.1016/S2213-8587(18)30290-0. Epub 2018 Nov 2.

PMID:
30396865
42.

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome.

Correa S, Morrow DA, Braunwald E, Davies RY, Goodrich EL, Murphy SA, Cannon CP, O'Donoghue ML.

J Am Heart Assoc. 2018 Oct 16;7(20):e009077. doi: 10.1161/JAHA.118.009077.

43.

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.

Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, Sritara P, Mercuri MF, Kamphuisen PW, Antman EM, Braunwald E, Giugliano RP.

J Am Heart Assoc. 2018 Aug 21;7(16):e008987. doi: 10.1161/JAHA.118.008987.

44.

Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).

Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL.

Am J Cardiol. 2019 Jan 1;123(1):145-152. doi: 10.1016/j.amjcard.2018.09.014. Epub 2018 Sep 26.

PMID:
30366601
45.

Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).

Korjian S, Braunwald E, Daaboul Y, Mi M, Bhatt DL, Verheugt FWA, Cohen M, Bode C, Burton P, Plotnikov AN, Gibson CM.

Am J Cardiol. 2018 Dec 1;122(11):1896-1901. doi: 10.1016/j.amjcard.2018.08.034. Epub 2018 Sep 7.

46.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.

Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP.

Eur Heart J. 2018 Nov 7;39(42):3810-3820. doi: 10.1093/eurheartj/ehy556.

47.

Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.

Corbalán R, Nicolau JC, López-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, Horna M, Ruff CT, Hamershock RA, Grip LT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2018 Sep 25;72(13):1466-1475. doi: 10.1016/j.jacc.2018.07.037.

48.

D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).

AlKhalfan F, Kerneis M, Nafee T, Yee MK, Chi G, Plotnikov A, Braunwald E, Gibson CM.

Am J Cardiol. 2018 Nov 1;122(9):1459-1464. doi: 10.1016/j.amjcard.2018.07.032. Epub 2018 Aug 4.

PMID:
30217378
49.

Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status.

Ambrosy AP, Cerbin LP, Fudim M, Clare RM, Lokhnygina Y, Braunwald E, Califf RM, Cannon CP, Tershakovec AM, Roe MT, Blazing MA.

Am J Cardiol. 2018 Nov 1;122(9):1451-1458. doi: 10.1016/j.amjcard.2018.07.034. Epub 2018 Aug 4.

PMID:
30180960
50.

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.

Zelniker TA, Braunwald E.

J Am Coll Cardiol. 2018 Oct 9;72(15):1845-1855. doi: 10.1016/j.jacc.2018.06.040. Epub 2018 Jul 31. Review.

Supplemental Content

Loading ...
Support Center